Read More

Valneva Says Single Chikungunya Vaccine Shows Long-Lasting Antibody Response In Younger, Older Adults

Valneva SE (NASDAQ: VALN) reported antibody persistence data 24 months after vaccination with a single dose of its chikungunya vaccine IXCHIQ, further supporting the anticipated long-term durability of the immune response and in line with positive twelve-month persistence data the company reported 

VALN

Read More

Why Is Age-Related Blindness Focused EyePoint Pharmaceuticals Stock Trading Over 300% Today?

EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) announced topline results of its Phase 2 DAVIO 2 trial of EYP-1901, an investigational sustained delivery maintenance treatment for wet age-related macular degeneration (wet AMD) combining vorolanib, a selective tyrosine kinase inhibitor with 

EYPT